Table of Contents
Chemotherapy Research and Practice
Volume 2011, Article ID 602812, 6 pages
Clinical Study

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
2Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221 Stanford, CA 94305, USA
3Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA

Received 18 April 2011; Revised 12 June 2011; Accepted 8 July 2011

Academic Editor: Evangelia D. Razis

Copyright © 2011 Seema Nagpal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To quantify the benefits in survival and quality of life in patients receiving bevacizumab (BEV) for recurrent glioblastoma (GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. All patients had initial treatment with surgery, radiation, and concurrent temozolomide, then monthly temozolomide. Over 250 charts were screened. Sufficient data was available for 20 patients treated with BEV and 20 patients who did not receive BEV at the time of recurrence. The independent living score (ILS), designed to reward long-term independent survival, was calculated for each patient. Results. The mean ILS was nearly double in the BEV group compared to the No-BEV group (15.0 versus 8.2, 𝑃 = 0 . 0 0 2 , t-test). Two months after initiation of therapy, the median steroid dose dropped by over 90% in patients treated with BEV, but doubled in the NoBEV group. Median survival from the time of recurrence was significantly affected: 10.6 months in the BEV group versus 4.2 months ( 𝑃 < 0 . 0 0 1 , log rank survival) in the NoBEV group. Conclusions. BEV increases independent living and lengthens overall survival after GBM recurrence. Reduction in steroid dose may contribute to prolonged independence.